iShares Biotechnology ETF

First Trust NYSE Arca Biotechnology Index Fund (FBT) and iShares Biotechnology ETF (IBB) offer different approaches to biotech sector exposure. FBT uses a concentrated 30-stock portfolio with higher returns (53.2% one-year, 168% ten-year) but greater risk, while IBB provides broader diversification with 248 holdings and lower fees (0.44% vs 0.55%...

The Nasdaq 100 fell 0.7% as chip stocks stumbled, with Broadcom cratering 15% despite beating earnings due to weak AI-chip revenue guidance. The Dow Jones rallied 1.7% on defensive and financial strength, while the S&P 500 remained flat. Bitcoin hit a 4-month low at $61,310. Other tech stocks like CrowdStrike, Ciena, and Five Below also declined ...

Major pharmaceutical companies face a patent cliff with $175 billion in annual drug sales losing exclusivity over the next six years, prompting increased M&A activity. Two biotech ETFs—SPDR S&P Biotech (XBI) and iShares Biotechnology (IBB)—offer investors exposure to capitalize on industry volatility and potential winners from consolidation.

Nextech Invest, a Switzerland-based biotech-focused fund, increased its stake in Relay Therapeutics by 855,097 shares (~$6.1 million). The purchase brings Relay to 3.85% of Nextech's portfolio. Relay's stock has surged 197% over the past year, driven by its computational drug discovery platform and clinical-stage pipeline including lead candidate...

Vertex Pharmaceuticals shares surged 6.32% in premarket trading after announcing positive Phase 3 RAINIER trial results for its kidney drug povetacicept. The trial met its primary objective with a 52% reduction in urine protein and 49.8% reduction versus placebo. An analyst upgraded the probability of success to 90% ahead of expected FDA approval...